Abstract Drug-resistant staphylococci constitute a serious problem that urgently requires the discovery of new therapeutic agents. There has been a resurgence in interest in using lysostaphin (a specific anti-staphylococcal enzyme) as a treatment for infections caused by these important pathogens. However, bacterial resistance to lysostaphin is a problem, but the use of a combination treatment may surmount this issue. In this present study, using viable counts from suspension incubations, lysostaphin is shown to be synergistically bactericidal in combination with various conventional antimicrobial peptides, the antimicrobial protein bovine lactoferrin, a lantibiotic (nisin), and certain lipopeptides used clinically (colistin, daptomycin and polymyxin B). Combinations that act in synergy are of clinical importance as these reduce the doses of the compounds needed for effective treatments and decrease the chances of resistance being selected. The use of lysostaphin in combination with a peptide may represent a new avenue in tackling drug-resistant staphylococci.
Introduction
The increased incidence in drug-resistant staphylococci has hastened the search for new compounds to treat infections caused by these pathogens. Since the 1960s, one compound that has attracted attention as a potential anti-staphylococcal treatment is the endopeptidase lysostaphin [1, 2] . This 27-kDa enzyme specifically cleaves cross-linking pentaglycine bridges that are found exclusively in the staphylococcal cell wall [3] . Staphylococcus aureus is particularly susceptible to lysostaphin because of the very high proportion of pentaglycine bridges found within its cell wall [3] . Historically, lysostaphin suffered from problems with immunogenicity and reliability of supply, but these issues have been resolved thanks to new technologies meaning that highly pure enzyme can be produced in great quantities [4] [5] [6] . This has seen renewed interest in using lysostaphin for antimicrobial applications [3, [7] [8] [9] [10] [11] . Nonetheless, one drawback with lysostaphin is the high preponderance for bacterial resistance to be selected through mutations in lyrA or the fem operon [12] [13] [14] . However, therapies that contain multiple antimicrobial agents can reduce the opportunity for resistance to be selected and various lysostaphin-containing combination treatments have been investigated, including lysostaphin with:
1. Various antibacterial drugs used clinically [7, 8, 13, [15] [16] [17] [18] [19] [20] 2. Tea tree oil [8] 3. Lysozyme [21] 4. The phage lytic enzyme LysK [22] 5. Certain conventional antimicrobial peptides (AMPs) [10, 15, 19, 23] The incorporation of an AMP into a combination therapy further reduces the opportunity for bacterial resistance, as these compounds typically disrupt the bacterial cell membrane and resistance to AMPs is reported only rarely [24] [25] [26] [27] . Moreover, certain lysostaphin/AMP combinations are synergistically antibacterial, which has clinical relevance as the doses of each compound can be reduced [10, 15] . The synergistic bactericidal combination of lysostaphin with ranalexin (an AMP first isolated from the American bullfrog, Rana catesbeiana) is more effective against wound MRSA infections in a rabbit model than treatment with either component alone [10] . This combination retains synergistic antibacterial activity when incorporated into a gel meaning that it could also be used topically or intranasally to reduce patient carriage of staphylococci [28] . However, there is some indication of the toxicity of ranalexin at higher concentrations in vitro [10] and the selection of a less toxic, but similarly potent peptide partner for lysostaphin warrants investigation to improve the overall safety of the treatment. Thus, the aim of this present study was to investigate the scope of bactericidal synergy between lysostaphin and a spectrum of diverse antimicrobial peptides with the ultimate goal of providing new products for preventing and treating staphylococcal infections. Table 1 . Peptide stocks and all other solutions were made with ultra pure de-ionised water (Maxima; Elga, High Wycombe, UK). Solutions and culture media were autoclaved at 121°C for 15 min or filtersterilised (polyethersulphone 0.22 μm; Millipore, Watford, UK). S. aureus strains were sourced as described previously [10] . Bacterial suspensions were made in tryptone soy broth (TSB) using cultures, which had been grown to lateexponential phase in this medium at 220 rpm and 37°C.
Haemolysis assay
The toxicity of each peptide was assessed by haemolysis using horse and sheep red blood cells (RBCs) according to the method of Desbois et al. [10] . To 100 μL RBC suspensions was added 0.5, 1 or 2 μL of peptide solution to give concentrations of 32, 64 and 128 mg L −1 (for nisin and polymyxin B greater volumes were added due to the use of less concentrated stock solutions). RBCs suspended in 1% sodium dodecyl sulphate were positive controls (100% haemolysis). Percentage haemolysis at 4 h was calculated for each well.
Suspension assay for bactericidal activity
To wells on a 96-well plate was added 96 μL of bacterial suspensions in TSB (1 × 10 6 cfu mL
; exponential phase), which was made up to 100 μL by the addition of stock solutions to give various final well concentrations of peptide alone, lysostaphin alone or peptide with lysostaphin. The concentrations of lysostaphin and/or peptide were selected for the assays on the basis of the susceptibility of each bacterium to the compound(s) under investigation and those that most effectively demonstrated the synergy between the compounds (up to a maximum of 128 mg L
−1
). To control wells was added water only and each treatment was performed in quadruplicate. The plate was incubated (37°C; 24 h; 1,000 rpm) on a microplate thermoshaker (PHMP; Grant Instruments Ltd., Shepreth, UK). After incubation, viable bacteria were determined for each well by serial dilution in phosphate-buffered saline (PBS; for 1 L: 8 g NaCl, 0.2 g KCl, 1.15 g Na 2 HPO 4 , 0.2 g KH 2 PO 4 ; pH 7.3) and plating on tryptone soy agar (TSA). Plates were incubated (37°C; 24 h) and colony counts performed. The detection limit for each well was 100 cfu mL . The number of colonies recovered from replicate wells for each treatment were transformed by log 10 and then averaged to give the geometric mean. Bactericidal synergy is defined as a >2 log 10 cfu mL −1 reduction by the combination treatment compared with its most active constituent, providing that the number of viable bacteria recovered from the combination treatment is >2 log 10 cfu mL −1 lower than the starting inoculum [30] . Further, at least one of the components in the combination must not affect the viability of the test organism when used alone [30] .
Results
Most of the peptides caused little or no haemolysis (<2% haemolysis of horse or sheep RBCs even at 128 mg L −1 )
indicating that these probably have a low propensity for acute toxicity to mammalian cells (Table 1) . Nigrocin caused 27.7% haemolysis of horse RBCs at 128 mg L −1 , but this was still not as toxic as ranalexin, which caused 64.4% haemolysis at this concentration (Table 1 ).
In the bactericidal activity assays, when lysostaphin or each of the peptides was incubated individually with suspensions of S. aureus Newman (a methicillin-susceptible strain), these compounds had little or no effect on the number of viable bacteria recovered after 24 h compared with controls (Table 2) . However, when lysostaphin was used in combination with each of the peptides (at the same concentrations as the individual incubations), counts of viable bacteria were reduced to such an extent that these treatments demonstrated synergistic bactericidal activity in each case. In many of the combinations, the number of viable bacteria recovered from the wells was at the limit of detection. Similar results were achieved using a methicillin-resistant (MRSA) strain, S. aureus BB270 (Table 3) , thus confirming the synergistic bactericidal interactions between lysostaphin and the various peptides under investigation. 
Discussion
This study shows for the first time bactericidal synergy for lysostaphin in combination with various conventional AMPs, lipopeptides and bovine lactoferrin.
In a previous study, while there were no signs of toxicity for lysostaphin/ranalexin combination treatments in animal infection models, ranalexin was toxic at high concentrations to horse RBCs and Vero cells [10] . Thus, it was deemed prudent to investigate a less toxic peptide partner for lysostaphin. In this present study, ranalexin is confirmed to be acutely toxic to horse RBCs at high concentrations, but, with the exception of nigrocin, no other peptide used in this study is haemolytic. Previous studies have shown that lysostaphin acts in synergy against S. aureus with certain antimicrobial peptides [10, 15, 19] . In the present study, the reported antibacterial synergy of lysostaphin with dermaseptin S3 (1-16) , magainin, polymyxin B and ranalexin is confirmed. Each of the other peptides used herein also acts in synergy with lysostaphin to kill staphylococci. Thus, lysostaphin renders S. aureus more susceptible to a broad spectrum of peptides, including conventional AMPs, lipopeptides, the lantibiotic nisin and the antimicrobial protein bovine lactoferrin. However, the synergies reported here have yet to be quantified and further studies to this end are warranted. Such investigations will identify the combinations with greatest promise for future anti-staphylococcal applications, but, on initial inspection, some combinations appear more appealing as they contain compounds already used clinically (e.g. colistin, daptomycin and polymyxin B) or that have been evaluated in clinical trials (e.g. pexiganan). In addition, any synergism observed in vitro must be evaluated in animal infection models to confirm that the favourable interaction is repeated in vivo because this cannot necessarily be assumed. Lysostaphin kills staphylococcal bacteria by cleaving the pentaglycine bridges in the cell wall [3, 31] , while most of the peptides used in this study act against bacteria by affecting the integrity and functioning of the cell membrane (e.g. [25, [32] [33] [34] [35] [36] [37] ). Therefore, synergistic bactericidal activity could result from the peptide having greater access to the cell membrane thanks to the cell wall-degrading ability of lysostaphin.
Lysostaphin has attracted renewed attention as a viable antimicrobial therapy in the light of increasingly prevalent multi-drug resistance. Reliable supplies of highly pure lysostaphin are now available and its use in combination with antimicrobial peptides may surmount the problem of bacterial resistance to lysostaphin alone [10] . Moreover, synergistic combinations have greater appeal as lower doses of the active compounds can be used. The vast majority of antimicrobial peptides tested in this present study act in synergy with lysostaphin and are non-toxic at effective concentrations meaning that they are highly suitable partners in combination treatments. Lysostaphin/peptide combinations may be useful for topical decolonisation therapy in the prevention of infection, but may also find application in wound therapy.
